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INTRODUCTION
Uncompensated heart failure (UHF) is a leading cause of
hospitalization. The available drugs to treat acute UHF
include inotropes, diuretics and vasodilators. In recent
years, hypertonic saline (HTS) has emerged as a new
potential therapy for refractory heart failure, usually in
association with high doses of diuretics. However, there
have been no reports describing the use of HTS as a first-line
treatment for UHF. Here, we report a case in which a 10%
NaCl solution was used as the primary therapy for a patient
with UHF. Almost immediately, hypertonic saline was able
to restore the patient’s hemodynamic profile and to
eliminate Cheyne-Stokes respiration (CSR), which is asso-
ciated with a low cardiac output state.
CASE DESCRIPTION
A 90-year-old man was admitted to the intensive care unit
(ICU) because of dyspnea and lethargy. The patient had been
diagnosed with prostatic cancer ten years before but had not
received chemotherapy in the last two years. He also had
chronic congestive heart failure with atrial fibrillation,
probably related to arterial hypertension. His current
prescriptions included furosemide (40 mg once a day) and
captopril (25 mg twice daily). He had been institutionalized
in a hospice for the previous six months and had symptoms
of dyspnea after performing light to moderate activities.
Upon admission, the patient was somnolent (hypoactive
delirium) and exhibited no focal neurologic signs. He
complained of shortness of breath and lower back pain.
His extremities were cold and had delayed capillary refill
(about 4 seconds). The patient’s blood pressure was 74/
46 mmHg, and his heart rate was 120 beats per minute
(atrial fibrillation). His central venous pressure was clini-
cally estimated to be 17 cm of water. His breathing pattern
was periodic and presented as apnea interspersed with
faster and deeper breaths, which we determined to be
Cheyne-Stokes respiration (CSR). He received supplemen-
tary oxygen through a nasal catheter at two liters per minute
with a peripheral arterial O2 saturation of 99%. Rales were
detected throughout the length of the patient’s hemi-
thoraces.
Laboratory exams showed a moderate level of metabolic
acidosis, with a pH of 7.20, a low bicarbonate level of
17.8 mEq/L and a standard base excess of -10 mmol/L. His
carbon dioxide level was slightly elevated at 46.3 mmHg, his
lactate level was 2 mmol/L, and there were no electrolyte
disorders detected. Initial troponin and creatine kinase-MB
were both within normal ranges. Echocardiography was not
available at the time.
A diagnosis of cardiogenic shock was established. After
meeting with the patient’s family, it was decided to treat the
patient without invasive mechanical ventilation, dialysis,
central venous puncture or vasoactive amines. The patient
also refused noninvasive mechanical ventilation. Because
the patient had already received 1L of 0.9% NaCl before ICU
admission, only a small fluid challenge of 250 mL of lactated
Ringer’s solution was administered. However, no improve-
ment in the patients parameters was observed. A low dose
of dobutamine was administered, but the patient developed
several episodes of non-sustained ventricular tachycardia
and hypotension, so dobutamine administration was
stopped. Additionally, nitrates were not administered due
to the patient’s low arterial blood pressure. Nesiritide was
not available at the time. Therefore, we decided to try
hypertonic saline infusion as a final, non-invasive approach
to improve myocardial contractility. We infused 100 mL of
10% NaCl over a period of 10 minutes.
Less than three minutes after the infusion, the patient’s
breathing pattern improved, with the progressive reduction
in the time of peak ventilation, cycle length, apnea length
and ventilation length. Finally, the patient’s breathing
pattern returned to normal (figure 1). The patient’s blood
pressure increased to 110/70 mmHg, and his heart rate
decreased to 106 beats per minute. His capillary refill time
also improved. One hour later, intravenous infusion of a
low dose of nitroprusside was performed, which was well
tolerated by the patient. The patient was discharged from
the ICU after being treated with oral vasodilators for an
additional few days.
DISCUSSION
Recently, the use of hypertonic saline was proposed as
a treatment for refractory heart failure associated with
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high-dose diuretic therapy, with promising results.1 Most of
the data available on the use of HTS are from chronic
ambulatory patients, with only one report from an acute-
care setting. Additionally, these data were generally from
patients with cardiogenic shock resulting from right
ventricular infarction.2 Another report also evaluated the
use of hypertonic saline as an adjunct therapy in uncom-
pensated heart failure patients and indicated that hyper-
tonic saline had positive effects on renal function.3 In
experimental models, hypertonic saline improved myocar-
dial contractility,4 but its immediate impact on the hemo-
dynamic profile during acute UHF has not been studied or
reported to date. In the present case study, hypertonic saline
was the only available non-invasive option for the treatment
of the patient. Its use improved the patient’s blood pressure
so that vasodilators could effectively be used. No side
effects were observed after the infusion. To our knowledge,
this is the first report of the use of HTS as the primary
therapy in the management of UHF.
HTS infusion also restored the patient’s normal breathing
pattern. Periodic pattern breathing and CSR are both
associated with UHF and low cardiac output states.5 In
ambulatory patients, CSR is associated with increased
mortality, impeded exercise capacity and arrhythmias.5
The pathophysiology of CSR is complex and appears to
involve circulation delay, increased chemoreceptor sensi-
tivity and hyperventilation or hypocapnia.5
We hypothesize that HTS administration exerted a
beneficial effect on the patient’s myocardial contractility
and improved his cardiac output, which reduced his
periodic breathing pattern and improved his blood pres-
sure. Interestingly, this improvement occurred in under
three minutes (figure 1). Unfortunately, due to the quick
action of HTS, we were unable to measure cardiac output
before and after infusion. However, the possibility that the
hypertonic solution exerted a direct effect on breathing
control mechanisms (especially on chemoreceptors) cannot
be excluded.
In conclusion, hypertonic saline was able to restore
hemodynamic parameters and breathing patterns almost
immediately after administration to a patient suffering from
uncompensated heart failure. Therefore, hypertonic saline
may be an attractive therapeutic option for the initial
management of UHF. These data suggest that randomized
controlled trials to evaluate the role of HTS early in the
treatment of UHF are clearly warranted.
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Figure 1
Use of hypertonic saline to treat uncompensated heart failure
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